Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/150.1)
  • Patent number: 6290960
    Abstract: The present investion provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are produced with portions of C. difficile Toxin A, or Toxin B, or both. These portions of Toxins A and B may be fusion proteins with at least one non-toxin protein sequence, and may also be soluble and substantially endotoxin-free. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: September 18, 2001
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: John A. Kink, Bruce S. Thalley, Douglas C. Stafford
  • Patent number: 6291649
    Abstract: An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunogenically active form, antibodies against which determinant react with the adhesin polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, antibodies against such antigen, and DNA expressing, as a principal gene product thereof, such antigen.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: September 18, 2001
    Assignee: Symbicom Aktiebolag
    Inventors: Frederik Carl Lindberg, Björn Olof Lund, Britt Monika B{dot over (a)}ga, Mari Elisabet Norgen, Mikael Göransson, Bernt Eric Uhlin, Jan Staffan Normark, David Lee Lark
  • Patent number: 6291178
    Abstract: A method and apparatus for the preservation of a saliva sample for use in subsequent quantitative chemical assays. The method involves collecting a saliva sample at a location, directly into a specimen cup. The specimen cup contains a predetermined volume of aqueous solution of pH buffered saline and enzymatic inhibitor and is optionally adapted with a constituent compound specific, qualitative test unit.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: September 18, 2001
    Inventor: David R. Schneider
  • Patent number: 6290959
    Abstract: Uroplakins Ia and Ib are the major urothelial receptors of type 1 fimbriated microorganisms. These uroplakins are used to screen compounds for treating urinary tract infections by testing if the compounds inhibit bacterial adhesion to the uroplakins. Additionally, compounds which inhibit adhesion of microorganisms expressing type 1 fimbriae, such as Tamm-Horsfall protein, are used to treat or inhibit infection by these microorganisms.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: September 18, 2001
    Assignee: New York University
    Inventors: Xue-Ru Wu, Tung-Tien Sun
  • Patent number: 6288214
    Abstract: Disclosed are the cna gene and cna-derived nucleic acid segments from Staphylococcus aureus, and DNA segments encoding cna from related bacteria. Also disclosed are Col binding protein (CBP) compositions and methods of use. The CBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological infections, and in particular, for use in the prevention of bacterial adhesion to Col. DNA segments encoding these proteins and anti-(Col binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of bacterial colonization in an animal such as a human. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of S. aureus infection.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: September 11, 2001
    Assignee: Texas A&M University Systems
    Inventors: Magnus Höök, Joseph M. Patti, Karen House-Pompeo, Narayana Sthanam, Jindrich Symersky
  • Patent number: 6258359
    Abstract: There is provided an immunogenic composition capable of inducing protective antibodies against Helicobacter infection characterized in that it comprises: i) at least one sub-unit of a urease structural polypeptide from Helicobacter pylori (SEQ ID NO: 22,26), or a fragment thereof, said fragment being recognized by antibodies reacting with Helicobacter felis urease (SEQ ID NO: 20-21), and/or at least one sub-unit of a urease structural polypeptide from Helicobacter felis (SEQ ID NO: 20-21), or a fragment thereof, said fragment being recognized by antibodies reacting with Helicobacter pylori urease (SEQ ID NO: 22-26); ii) and/or, a heat shock protein (Hsp), or chaperonin, from Helicobacter, or a fragment of said protein. The preparation, by recombinant means, of such immunogenic compositions is also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 10, 2001
    Assignee: Institut Pasteur
    Inventors: Agnes Labigne, Sebastian Suerbaum, Richard L. Ferrero, Jean-Michel Thiberge
  • Patent number: 6248517
    Abstract: Disclosed are the dbp gene and dbp-derived nucleic acid segments from Borrelia burgdorferi, the etiological agent of Lyme disease, and DNA segments encoding dbp from related borrelias. Also disclosed are decorin binding protein compositions and methods of use. The DBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological Borrelia infections, and in particular, for use in the prevention of bacterial adhesion to decorin. DNA segments encoding these proteins and anti-(decorin binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of Borrelia colonization in an animal. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of Lyme disease.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: June 19, 2001
    Assignee: The Texas A & M University System
    Inventors: Betty P. Guo, Magnus H{umlaut over (oo)}k
  • Patent number: 6245331
    Abstract: A number of protein and glycoprotein antigens secreted by Mycobacterium. tuberculosis (Mt) have been identified as “early” Mt antigens on the basis early antibodies present in subjects infected with Mt prior to the development of detectable clinical disease. These early Mt antigens, in particular an 88 kDa secreted protein having a pI of about 5.2 present in Mt lipoarabinomannan-free culture filtrate, a protein characterized as Mt antigen 85C; a protein characterized as Mt antigen MPT51, a glycoprotein characterized as Mt antigen MPT32; and a 49 kDa protein having a pI of about 5.1, are useful in immunoassay methods for early, rapid detection of TB in a subject. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mt antigen, an early Mt antibody, and immune complexes thereof.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: June 12, 2001
    Assignees: New York Univ. Medical Center, Colorado State University
    Inventors: Suman Laal, Susan Zolla-Pazner, John T. Belisle
  • Patent number: 6221353
    Abstract: Antibodies that bind Mycobacterium tuberculosis 28 kDa proteins and immune complexes between the antibodies and proteins.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: April 24, 2001
    Assignee: Institut Pastuer
    Inventors: Anne Laqueyrerie, Gilles Marchal, Pascale Pescher, Felix Romain
  • Patent number: 6218166
    Abstract: Disclosed are compositions and methods for enhancing the antibody and T cell response to cellular antigens by incorporating an immunopotentiating agent into the cellular membrane or into an intracellular compartment. Such adjuvant-incorporated cell compositions are useful in methods to increase immune responses against antigens, including immunologically cryptic tumor cell antigens, and may be employed to generate useful diagnostic antibodies, to elicit anti-tumor effects in immunized animals, and to significantly prolong survival in animals with cancer.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 17, 2001
    Assignee: John Wayne Cancer Institute
    Inventors: Mepur H. Ravindranath, Donald L. Morton
  • Patent number: 6214341
    Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: April 10, 2001
    Assignee: OraVax
    Inventors: William D. Thomas, Jr., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
  • Patent number: 6168790
    Abstract: The present invention concerns a method of treating bacteremia, sepsis and other forms of toxemia caused by Gram-positive bacteria and mycobacteria comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: January 2, 2001
    Assignee: The Scripps Research Institute
    Inventors: Richard J. Ulevitch, Peter S. Tobias, Jerome Pugin